Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock Price Up 5.4% – Time to Buy?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) shares were up 5.4% on Wednesday . The company traded as high as $23.75 and last traded at $24.08. Approximately 164,218 shares were traded during trading, a decline of 89% from the average daily volume of 1,473,637 shares. The stock had previously closed at $22.84.

Analysts Set New Price Targets

A number of equities research analysts recently commented on CPRX shares. Truist Financial upped their target price on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, November 11th. StockNews.com lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 11th. Stephens started coverage on Catalyst Pharmaceuticals in a research report on Monday, November 18th. They issued an “overweight” rating and a $35.00 price objective on the stock. HC Wainwright upped their price target on Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, January 10th. Finally, Bank of America restated a “buy” rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $32.86.

Catalyst Pharmaceuticals Stock Down 2.8 %

The company has a market capitalization of $2.78 billion, a PE ratio of 20.11, a price-to-earnings-growth ratio of 2.39 and a beta of 0.79. The firm has a 50-day moving average of $21.96 and a two-hundred day moving average of $20.65.

Insider Activity

In other news, insider Steve Miller sold 50,000 shares of the stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total value of $1,096,500.00. Following the transaction, the insider now owns 686,996 shares in the company, valued at approximately $15,065,822.28. This represents a 6.78 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Gary Ingenito sold 12,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total value of $272,640.00. Following the sale, the insider now owns 51,391 shares of the company’s stock, valued at approximately $1,167,603.52. The trade was a 18.93 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 79,500 shares of company stock valued at $1,754,140. 11.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Catalyst Pharmaceuticals

A number of large investors have recently made changes to their positions in the company. GAMMA Investing LLC raised its holdings in shares of Catalyst Pharmaceuticals by 62.1% in the third quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 681 shares during the last quarter. nVerses Capital LLC purchased a new position in shares of Catalyst Pharmaceuticals in the 3rd quarter valued at approximately $50,000. Larson Financial Group LLC increased its holdings in shares of Catalyst Pharmaceuticals by 27,218.2% in the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock valued at $60,000 after purchasing an additional 2,994 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in Catalyst Pharmaceuticals in the 4th quarter valued at $65,000. Finally, KBC Group NV increased its stake in Catalyst Pharmaceuticals by 48.8% in the 4th quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company’s stock valued at $98,000 after buying an additional 1,542 shares during the period. 79.22% of the stock is owned by institutional investors and hedge funds.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.